Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
17/12/2025 12:09
Dec 17 (Reuters) - Compugen Ltd CGEN.TA: COMPUGEN MONETIZES PORTION OF RILVEGOSTOMIG FUTURE ROYALTIES TO ASTRAZENECA FOR UP TO $90 MILLION COMPUGEN LTD - DEAL EXPECTED TO EXTEND CASH RUNWAY INTO 2029 COMPUGEN LTD - RETAINS MAJORITY OF ROYALTIES FOR LONG-TERM UPSIDE Further company coverage: CGEN.TA
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025